Clinical Trial Update: Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia [Phase 2]

View source ↗

Summary

This clinical trial update reports the results of a Phase 2 efficacy and safety comparison of CEM-101 versus levofloxacin for treating community-acquired pneumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• CEM-101
• Levofloxacin (Levofloxacin)

Snippet

Sponsor: Melinta Therapeutics, Inc. | Conditions: Community-Acquired Bacterial Pneumonia | Phase 2 | Status: COMPLETED